

## Press Release

17 May 2022 08:45:00 CEST

# Three IndiTreat® posters have been accepted at ESMO-GI 2022

Three IndiTreat® posters have been accepted at the World Congress on Gastrointestinal Cancer, hosted in Barcelona by the European Society for Medical Oncology (ESMO) from June 29th to July 2nd 2022.

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today that the three IndiTreat® posters submitted to the ESMO GI conference by the company and its clinical partners University Clinic Eppendorf – Hamburg, Germany – and University Hospital Vejle – Vejle, Denmark – have been accepted by the organization and will be presented and discussed at the conference.

The posters:

- #546: In vitro drug screening of patient-derived 3D tumoroids replicates resistance to FOLFOX, FOLFIRI, and FOLFOXIRI in clinically resistant patients with metastatic colorectal cancer
- #212: Precision oncology without biomarkers: Assessing drug sensitivity in patient-derived tumoroids to guide mCRC 3rd line therapy
- #668: In vitro drug screening of patient-specific tumoroids to predict chemotherapeutic treatment response in Pancreatic ductal adenocarcinoma: An interim analysis

... highlight the benefits of the current IndiTreat® products (mCRC Start, mCRC Extend and mCRC Explore) as well as the advances in developing a new application for Pancreatic cancer.

### Focusing on the impact on first-line mCRC patients

“It is exciting to see that all the abstracts we submitted have been accepted”, says **Ole Thastrup**, 2cureX’s CSO. “Our focus last year was on the positive impact of the IndiTreat® test for third-line metastatic colorectal cancer (mCRC) patients. This year we are emphasizing the impact on first-line mCRC patients, as well as the progress of our Pancreatic cancer project”.

### Three posters, booth and important discussions with European oncologists

**Fernando Andreu**, CEO of 2cureX: “It’s the first time that 2cureX is present at a conference with three posters. ESMO GI is the most powerful meeting of GI oncologists in Europe. Beyond our scientific presence, we will have a booth that will give us a fantastic opportunity to discuss the IndiTreat® products and the IGNITE program with oncologists from all over Europe”.

The information presented here on the accepted abstracts is limited, in accordance with the *Guidance for Exceptions to ESMO's Confidentially Policy* regarding disclosure of confidential abstract in advance of public release date to satisfy requirements for a publicly traded company ([ESMO Congress 2022 Abstract Regulations](#)).

For more information about 2cureX:

---

Fernando Andreu, Chief Executive Officer

E-mail: [fa@2curex.com](mailto:fa@2curex.com)

Telephone: +45 2279 5399

[www.2curex.com](http://www.2curex.com)

Ole Thastrup, Chief Science Officer

E-mail: [ot@2curex.com](mailto:ot@2curex.com)

Telephone: +45 2211 5399

[www.2curex.com](http://www.2curex.com)

## About 2cureX

---

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The portfolio of IndiTreat® tests is aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® mCRC Start for first line of therapy, IndiTreat® mCRC Extend and IndiTreat® mCRC Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit [www.2cureX.com](http://www.2cureX.com)

Certified Adviser: Redeye AB, +46 8 121 576 90, [certifiedadviser@redeye.se](mailto:certifiedadviser@redeye.se)

## Attachments

---

[Three IndiTreat® posters have been accepted at ESMO-GI 2022](#)